Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2005

View Archived Issues

Antipsychotic effects of a new 5-HT2C receptor agonist from Pfizer

Curcumin and its metabolite highlighted as promising agents for neurologic disorders

JNJ-27291199, an Hdm2:p53 complex inhibitor, potentiates doxorubicin

NSC-67657: A CEBPalpha activator with antileukemic potential

Tanabe updates pipeline progress in H1 FY2005

Oscient files Factive sNDA for five-day treatment of new indications

Pfizer exercises option to NicOx collaborative compounds

Myriad Genetics and Abbott extend pharmacogenetics alliance

First patient enrolled in European phase III trial of Alzhemed

Large multivalent immunogen vaccine active in melanoma, renal cell carcinoma

Tocilizumab study results reveal efficacy in arthritis, systemic lupus erythematosus

Golimumab improves signs and symptoms of refractory rheumatoid arthritis

Oral cFMS kinase inhibitor GW-2580 inhibits CSF-1 signaling in vivo

ALK5 inhibition attenuates profibrotic signaling and fibrogenic response

Flow-induced arterial remodeling modified by cavtratin

Novartis reports novel CCR1 antagonists with activity in experimental arthritis

Clevudine demonstrates sustained activity in chronic hepatitis B patients

Lassa fever vaccine candidate developed

ENMD-1198 to enter clinical testing in 2006

Emergent BioSolutions tests single dose oral typhoid vaccine in Vietnam

Genzyme acquires Cell Genesys' San Diego manufacturing operation

Phase IIb HCV study to evaluate celgosivir plus Pegetron

ChemoCentryx seeks clearance to begin clinical studies of CCX-915

Enrollment begins in phase III Viprinex study for ischemic stroke

Phase III Oxytrex results in moderate to severe osteoarthritic pain

Allergan proposes to acquire Inamed

Xyrem approved to treat excessive daytime sleepiness in narcolepsy patients

Approvable letter for Vasovist

Pexelizumab fails to meet primary endpoint threshold for statistical significance

Recent Merck KGaA patent claims novel anticoagulant agents

Cardiovascular agents disclosed in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.